GH Secretagogue Systems: Ipamorelin, CJC-1295, and GHRP-6

Why GH Secretagogues Stack: Dual Pathway Amplification

Growth hormone release from the pituitary gland is controlled by two primary upstream signals: growth hormone releasing hormone (GHRH) and ghrelin. These two signals operate through completely separate receptor systems. GHRH binds to the GHRH receptor on somatotroph cells in the anterior pituitary. Ghrelin and ghrelin mimetics bind to the growth hormone secretagogue receptor type 1a (GHS-R1a). When both pathways are stimulated simultaneously, the GH pulse produced is not merely additive. Research consistently shows a synergistic amplification, meaning the combined response exceeds the sum of what each pathway would generate independently.

This is the central principle behind every two-peptide GH secretagogue stack. One peptide occupies the GHRH receptor pathway. One peptide occupies the ghrelin pathway. Together, they produce a GH pulse that neither could generate alone at the same individual dose. Understanding this mechanism determines which compounds you pair and why.

  HYPOTHALAMUS
      |
      |-- GHRH signal
      |
  ANTERIOR PITUITARY
      |
      |---- GHRH Receptor  <---  CJC-1295 (No DAC or with DAC)
      |                                   acts on this pathway
      |
      |---- GHS-R1a        <---  Ipamorelin / GHRP-6
      |    (Ghrelin R)              acts on this pathway
      |
      v
  GH PULSE (somatotrophs release GH)
      |
      v
  LIVER + PERIPHERAL TISSUES
      |
      v
  IGF-1 PRODUCTION  (primary feedback marker)
      

Ipamorelin: Mechanism Review

Ipamorelin is a synthetic pentapeptide ghrelin mimetic. Its five-residue sequence selectively binds to the GHS-R1a receptor with high affinity. What makes Ipamorelin clinically interesting as a research compound is its selectivity profile. Compared to older GHRPs, it does not significantly stimulate cortisol or prolactin release at standard research doses. This selectivity is not trivial. Cortisol is catabolic and antagonizes the anabolic downstream effects of GH. A compound that stimulates GH while simultaneously elevating cortisol partially cancels its own benefit. Ipamorelin largely avoids this.

The half-life of Ipamorelin is approximately two hours. Peak plasma concentration occurs within 15 to 30 minutes of subcutaneous administration. This means that if you administer Ipamorelin with the intention of amplifying the natural pre-sleep GH pulse, timing to 30 minutes before sleep onset is the working protocol. The GH pulse it helps produce aligns with the pulse that would naturally occur during slow-wave sleep.

CJC-1295 Without DAC: The Preferred Learning Compound

CJC-1295 without DAC is a synthetic analog of growth hormone releasing hormone. It occupies the GHRH receptor pathway rather than the ghrelin pathway, making it the natural pairing partner for Ipamorelin. The "No DAC" designation means it does not contain a drug affinity complex, the molecular modification that would extend its half-life by enabling albumin binding.

Without the DAC modification, CJC-1295 has a half-life of approximately 30 minutes. This short half-life is considered advantageous in an educational protocol context for two reasons. First, it produces a discrete GH pulse that mimics the pulsatile pattern of endogenous GHRH release. The hypothalamus releases GHRH in pulses, not as a continuous signal. CJC-1295 No DAC preserves this pulsatile character. Second, the short action window gives the GH axis time to return to baseline between doses, reducing the risk of sustained somatotroph stimulation that could theoretically contribute to desensitization.

CJC-1295 With DAC: A Different Risk Profile

CJC-1295 with DAC extends the half-life to 6-8 days through albumin binding. A single injection produces sustained elevation of GHRH receptor stimulation over that entire period. This fundamentally changes the pharmacodynamic character of the compound from pulsatile to a continuous baseline elevation of GH. Some researchers prefer this approach for simplicity. The tradeoff is that continuous GH axis stimulation departs further from the endogenous physiological pattern, and the long half-life means that if an adverse effect appears, the compound cannot be rapidly cleared. For the purpose of understanding secretagogue stacking, CJC-1295 No DAC is the preferred educational reference compound.

GHRP-6: Educational Comparison

GHRP-6 is an older, first-generation growth hormone releasing peptide. It binds to the same GHS-R1a receptor as Ipamorelin but with a different selectivity profile. The key distinction relevant here is that GHRP-6 produces a significant ghrelin-like hunger effect. This occurs because the GHS-R1a receptor is expressed throughout the gut and hypothalamus, not only in the pituitary, and its activation has downstream effects on appetite regulation. This hunger side effect is notable enough that it is a primary reason Ipamorelin largely replaced GHRP-6 in research protocols where appetite stimulation is not a goal.

GHRP-6 is included here for educational comparison, not as a preferred compound. Understanding why Ipamorelin was developed as an improvement over GHRP-6 clarifies the selectivity principle that should guide compound selection across the entire curriculum.

Designing the Two-Peptide GH Stack

The standard educational reference stack combines Ipamorelin and CJC-1295 No DAC at 100 mcg each per injection. Both are administered at the same time, in the same subcutaneous injection or as simultaneous separate injections. The co-administration timing ensures both receptor pathways are stimulated within the same window, producing the synergistic pulse.

The pre-sleep injection is the highest-priority administration timing. Natural GH secretion is dominated by the first slow-wave sleep episode of the night. Augmenting this window aligns the pharmacological stimulus with an already-primed physiological state. For those pursuing performance objectives, a second administration pre-training is sometimes used, capitalizing on the GH pulse that exercise itself tends to trigger.

Pulse vs. Bleed Strategies

A GH "pulse" strategy is what the Ipamorelin plus CJC-1295 No DAC combination produces: discrete, time-limited elevations of GH that mimic the natural pulsatile secretion pattern. A GH "bleed" strategy refers to the sustained baseline GH elevation produced by long-acting compounds like CJC-1295 with DAC. The pulse strategy is considered more physiologically conservative because it maintains the off-periods during which the GH axis resets, receptor sensitivity is preserved, and feedback systems operate normally. The bleed strategy produces higher sustained GH and IGF-1 levels but trades physiological fidelity for sustained elevation.

IGF-1 as the Feedback Marker

Insulin-like growth factor 1 is the primary downstream marker of GH secretagogue activity. The liver produces IGF-1 in response to GH signaling. When you administer a GH secretagogue protocol, IGF-1 is the blood marker that tells you whether the GH axis is responding. Measuring GH directly is largely impractical because of its pulsatile nature and short half-life. A single blood draw will rarely capture a GH pulse. IGF-1, by contrast, is produced continuously and has a half-life of approximately 15 hours, making it a stable, measurable indicator of the cumulative GH axis output over recent days.

Baseline IGF-1 before starting any GH secretagogue protocol is mandatory for meaningful interpretation. Without a baseline, a post-protocol IGF-1 result tells you nothing about whether the protocol produced a change. A reference range result does not mean the protocol is not working if the baseline was already at the top of the reference range.

Cycle Design: 8 Weeks On, 4 Weeks Off

The standard cycle structure for GH secretagogue protocols is 8 weeks of active administration followed by 4 weeks of washout. This cycle length reflects two considerations. First, the downstream effects of GH secretagogue protocols, particularly increases in IGF-1 and changes in body composition, take weeks to materialize. A cycle shorter than 8 weeks does not allow sufficient time to assess whether the protocol is producing the intended biological response. Second, extended continuous use without washout periods may contribute to somatotroph desensitization and reduces the quality of the single-variable data you are generating.